United States · 
Who invested in Janux Therapeutics?
Janux Therapeutics's investors include OrbiMed, Correlation Ventures, RA Capital Management, Janus Henderson Investors and Samsara BioCapital.
United States · Funded startup
Who invested in Janux Therapeutics
Funding summaryUpdated 26 Oct 2026
$350Mraised across 1 round since 2024, from 1 source
- Latest round
- Round, $350MDec 2024
- Investors
- 5
The rounds
- Dec 2024Round$350M
Source recorded
Founders and team
From Janux Therapeutics's own website and the SEC filings it signed: 9 on the team.
- Jenna DalyVice President, Clinical Operations
- Judy VongVice President, Regulatory Affairs and Quality Assurance
- Matt WhitmireVice President, Finance
- Charles WinterChief Technical Officer
- Janeen DoyleChief Corporate and Business Development Officer
- Mandie Forman-SklanskyHead of Human Resources
- James PenningtonGeneral Counsel
- David CampbellExecutive Officer, Directori
- Tighe ReardonExecutive Officeri
On the board, as filediJake SimsonJay LichterPeter ThompsonSheila GujrathiStefan HellerVickie L. Capps
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Janux Therapeutics
How much has Janux Therapeutics raised?
Janux Therapeutics has raised $350M across 1 round since 2024.
When did Janux Therapeutics last raise?
Janux Therapeutics's most recent round was an Undisclosed round of $350M in Dec 2024.
What was Janux Therapeutics's biggest round?
Its most recent round, $350M in Dec 2024, is also its largest on record.
Who backed Janux Therapeutics first?
Janux Therapeutics's first round on record, in Dec 2024, was backed by OrbiMed, Correlation Ventures and RA Capital Management and 2 others.
What stage is Janux Therapeutics at?
Janux Therapeutics's latest named round is an Undisclosed round, in Dec 2024.
Where is Janux Therapeutics based?
Janux Therapeutics is based in the United States.
Companies like Janux Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.